Program Visegrad meeting

11. března 2026, sál Rubín, Clarion Congress Hotel Ostrava

16.45-17.00

Welcome reception, Hájek R. (Ostrava)

PART I: MULTIPLE MYELOMA

17.00-17.10

Isatuximab – RWE data in quadruplet era of MM treatment, Hájek R. (Ostrava)

17.10-17.25

Safe administration of modern immunotherapy in an outpatient setting using telemedicine and home adverse event, Šušolová B., Popková T. (Ostrava)

17.25-17.40

The effect of MYC rearrangements on myeloma survival, Mikala G. (Budapest)

17.40-17.55

Ixazomib in the daratumumab era, real world analysis, Gergely V. (Budapest)

17.55-18.10

COBRA Results and TITAN Proposal of the Polish Myeloma Consortium, Dytfeld D. (Poznań)

18.10-18.30 

Coffee break

PART II: CELL THERAPIES & IMMUNOMONITORING

18.30-18.45

Current state of allogeneic CAR-T cell generation, Celichowski P. (Ostrava)

18.45-19.00

Genetic aberrations in Multiple Myeloma Revealed by Optical Genome Mapping, Kardos B. (Budapest)

19.00-19.15

Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8 color flow cytometry panel reveals differences among products kinetics and persistence, Venglář O. (Ostrava)

19.15-19.30

Leveraging the cell competition phenomenon for cancer treatment, Bagó J.R. (Ostrava)

19.30-19.45

Bone marrow adipose tissue creates a plasma cell supporting niche within the bone marrow, Kellermayer Z. (Pécs)

PART III: DISCUSSION 

PARTNEREM SYMPOZIA